openPR Logo
Press release

Peptide Based Hematological Disorders Therapeutics Market Expected to Secure Notable Revenue Share during 2017-2022

12-10-2018 10:45 AM CET | Health & Medicine

Press release from: Fact.MR

Fact.MR

Fact.MR

Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production. Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide therapeutics market. However, the synthesis and purification of long peptides is challenging for the manufacturers. Also, the rise in modifications and the addition of more unnatural amino acids have further increased the complications in peptide synthesis. This makes the manufactures of peptides difficult, and therefore the gap between demand and supply is increasing. Also, the manufacturing of peptides is a costly process, which hampers the growth of the global peptide therapeutics market.

Get Free Sample Report here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=189

Haematological disorders are the disorders related to problems in blood and blood components such as red blood cells, white blood cells, platelets, blood vessels, lymph nodes, spleen, bone marrow and the problems related to the proteins involved in bleeding and clotting (haemostasis and thrombosis). Therapeutic peptides are used in the treatment of haematological disorders mentioned above. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately. 

This Fact.MR report on the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

4 Forecast Highlights on Global Peptide Based Hematological Disorders Therapeutics Market

As per the forecast of Fact.MR, the ecallantide segment is slated to touch a value of nearly US$ 120 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The ecallantide segment is estimated to account for more than one-fifth of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.

As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 115 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.  

As per the forecast of Fact.MR, by the end of 2022, North America peptide based hematological disorders therapeutics market is projected to reach nearly US$ 220 Mn, registering a robust CAGR over the forecast period.

As perFact.MR forecasts, the US peptide based hematological disorders therapeutics market is estimated to account for 88.6% revenue share of the global peptide based hematological disorders therapeutics market by 2017 end and is expected to gain in market share by 2022 over 2017.

Know the methodology behind the report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=189

Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022

As per the forecast of Fact.MR, the icatibant segment is expected to reach a value of nearly US$ 410 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Icatibant segment is expected to account for more than three-fourth of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.  

Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes Shire plc.

Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=189

Table of Content:

Global Peptide Based Hematological Disorders Therapeutics Market - Executive Summary
Global Peptide Based Hematological Disorders Therapeutics Market Overview
2.1. Introduction
     2.1.1. Global Peptide Based Hematological Disorders Therapeutics Market Taxonomy
     2.1.2. Global Peptide Based Hematological Disorders Therapeutics Market Definition
2.2. Global Peptide Based Hematological Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Hematological Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Hematological Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region
Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
     3.1.1. Icatibant Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
              3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Ecallantide Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region
Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
     4.1.1. Hospital Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
              4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
Continued……………..

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peptide Based Hematological Disorders Therapeutics Market Expected to Secure Notable Revenue Share during 2017-2022 here

News-ID: 1428026 • Views:

More Releases from Fact.MR

Vegan Flavors Market Is Slated To Reach US$ 18,324.3 Million At A CAGR Of 5.2% B …
The global vegan flavor market is estimated to be valued at US$ 11,078.2 million in 2024 and is forecast to reach a value of US$ 18,324.3 million by 2034, with a projected CAGR of 5.2% from 2024 to 2034 owing to the rising popularity of plant-based diets. The Vegan Flavor Industry sales study offers a comprehensive analysis on diverse features including production capacities, Vegan Flavor demand, product developments, sales revenue generation
Pesticide Inert Ingredients Market Is Projected To Reach A Value Of US$ 13,167.2 Million By 2034: Fact.MR Report
Pesticide Inert Ingredients Market Is Projected To Reach A Value Of US$ 13,167.2 …
The global pesticide inert ingredients market is estimated to attain a valuation of US$ 7,621.2 million in 2024. During the forecast period, 2024-2034, the demand for pesticide-inert ingredients is expected to advance at a 5.6% CAGR globally. By 2034, the industry is expected to have grown to a valuation of US$ 13,167.2 million in size. The Pesticide Inert Ingredients Industry sales study offers a comprehensive analysis on diverse features including production
Portable Bluetooth Speaker Market Is Projected To Reach A Value Of US$ 20,521 Million At A CAGR Of 10.6% By 2034
Portable Bluetooth Speaker Market Is Projected To Reach A Value Of US$ 20,521 Mi …
The global portable bluetooth speaker market is estimated to be valued at US$ 7,521.6 million in 2024. The market is anticipated to reach US$ 20,521 million by 2034, with a projected CAGR of 10.6% from 2024 to 2034. The Portable Bluetooth Speaker Industry sales study offers a comprehensive analysis on diverse features including production capacities, Portable Bluetooth Speaker demand, product developments, sales revenue generation and Portable Bluetooth Speaker market outlook
Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2034: Fact.MR Report
03-29-2024 | Health & Medicine
Fact.MR
Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2 …
The global atrial fibrillation devices market (心房細動装置市場) size stands at a valuation of US$ 6.52 billion in 2024, with forecasts predicting a surge to US$ 24.76 billion by the conclusion of 2034. Sales of atrial fibrillation devices worldwide are expected to witness an impressive compound annual growth rate (CAGR) of 14.3% from 2024 to 2034. In recent years, the global healthcare landscape has witnessed a significant surge in the prevalence of

All 5 Releases


More Releases for Peptide

Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established
What's driving the Customized Peptide Synthesis Market Growth? | Key Players are …
The customized peptide synthesis market is projected to generate a revenue of $390.0 million by 2024 as per a recent P&S Intelligence study. The market is being progressively driven by technological innovations, growing burden of cancer and infectious diseases, increasing investments and funding for protein-based research, and rising research activities in synthetic biology. Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample There are two main types of products available in the customized peptide synthesis
Customized Peptide Synthesis Market 2019-2024 by Top Key Players are GenScript, …
Customized peptide synthesis market is forecasted to generate revenue of $390.0 million by 2024. The market is mainly driven by increasing investments and funding for protein-based research, technological innovations, growing burden of cancer and infectious diseases, and increasing research activities in the field of synthetic biology. Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample The different types of products available in the customized peptide synthesis market are reagents and equipment. Reagents category is expected
Peptide Synthesis Market Increasing Demand & Latest Trend with Genscript, AnaSpe …
HTF MI recently introduced United States Peptide Synthesis Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Bachem, PolyPeptide, GL Biochem, Xinbang, Hybio, USVPeptides, Thermofischer, ScinoPharm, Genscript,
Global Peptide Therapeutics Market: Cancer Treatment to Surface as Key Applicati …
Market Research Reports Search Engine (MRRSE) has been acting as an impressive data source when it comes to evaluating various industrial verticals. The research report titled “Global Peptide Therapeutics Market” offers a clear insight about the Peptide Therapeutics assessed over the global platform. This analysis proves beneficial for readers & new investors who are aiming to enter the market for Peptide Therapeutics in the near future. Click to Request a Sample:
Peptide Based Cancer Therapeutics Marke For peptide based cancer therapeutics ov …
About Peptide Based Cancer Therapeutics Market Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug